The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced.
pmKate2-f-mem is a mammalian expression vector intended for far-red fluorescent labeling of plasma membrane in living cells. The vector encodes far-red fluorescent protein mKate2 (see reporter description) targeted to plasma membrane by 20 amino acid farnesylation signal from c-Ha-Ras [Aronheim et al., 1994; Hancock et al., 1991]. The farnesylation signal is fused to the mKate2 C-terminus.
Transiently transfected HeLa cells expressing mKate2 targeted to plasma membrane by 20-amino acid farnesylation signal from c-Ha-Ras.
Scale bar represents 10 μm. Image from Shcherbo et al., 2009.
mKate2 codon usage is optimized for high expression in mammalian cells (humanized) [Haas et al., 1996]. To increase mRNA translation efficiency, Kozak consensus translation initiation site is generated upstream of the mKate2-f-mem coding sequence [Kozak, 1987].
pmKate2-f-mem vector can be used as a source of mKate2-f-mem hybrid sequence. The vector backbone contains unique restriction sites that permit its excision and further insertion into expression vector of choice.
Note: The plasmid DNA was isolated from dam+-methylated
The vector backbone contains immediate early promoter of cytomegalovirus (PCMV IE) for protein expression, SV40 origin for replication in mammalian cells expressing SV40 T-antigen, pUC origin of replication for propagation in
SV40 early promoter (PSV40) provides neomycin resistance gene (Neor) expression to select stably transfected eukaryotic cells using G418. Bacterial promoter (P) provides kanamycin resistance gene expression (Kanr) in
Expression in mammalian cells
pmKate2-f-mem vector can be transfected into mammalian cells by any known transfection method. CMV promoter provides strong, constitutive expression of the mKate2-f-mem in eukaryotic cells. If required, stable transformants can be selected using G418 [Gorman, 1985].
Suitable host strains for propagation in
Location of features
PCMV IE: 1-589
Enhancer region: 59-465
TATA box: 554-560
Transcription start point: 583
Kozak consensus translation initiation site: 606-616
Start codon (ATG): 613-615
Last amino acid in mKate2: 1312-1314
Farnesylation signal: 1330-1389
Stop codon: 1390-1392
SV40 early mRNA polyadenylation signal
Polyadenylation signals: 1584-1589 & 1613-1618
mRNA 3' ends: 1622 & 1634
f1 single-strand DNA origin: 1681-2136
Bacterial promoter for expression of Kanr gene
-35 region: 2198-2203
-10 region: 2221-2226
Transcription start point: 2233
SV40 origin of replication: 2477-2612
SV40 early promoter
Enhancer (72-bp tandem repeats): 2310-2381 & 2382-2453
21-bp repeats: 2457-2477, 2478-2498 & 2500-2520
Early promoter element: 2533-2539
Major transcription start points: 2529, 2567, 2573 & 2578
Kanamycin/neomycin resistance gene
Neomycin phosphotransferase coding sequences:
Start codon (ATG): 2661-2663
Stop codon: 3453-3455
G->A mutation to remove Pst I site: 2843
C->A (Arg to Ser) mutation to remove BssH II site: 3189
Herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signal
Polyadenylation signals: 3691-3696 & 3704-3709
pUC plasmid replication origin: 4040-4683
mKate2-related materials (also referred to as "Products") are intended for research use only. The Products are covered by U.S. Pat. 7,638,615; European Pat. 1994149; and other Evrogen Patents and/or Patent applications pending. By use of these Products, you accept the terms and conditions of the applicable Limited Use Label License.
The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839, and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.
Copyright 2002-2018 Evrogen. All rights reserved.
Evrogen JSC, 16/10 Miklukho-Maklaya str., Moscow, Russia, Tel +7(495)988-4084, Fax +7(495)988-4085, e-mail:email@example.com